<DOC>
	<DOCNO>NCT00459615</DOCNO>
	<brief_summary>The purpose study compare four regimen use US FDA GMP intravenous artesunate treatment uncomplicated Plasmodium falciparum malaria identify effective treatment regimen determine rapidity parasite clearance microscopy .</brief_summary>
	<brief_title>Phase II Dose Ranging Study Artesunate</brief_title>
	<detailed_description>To compare efficacy tolerability intravenous artesunate initial treatment uncomplicated Plasmodium falciparum malaria dose bracket anticipate clinical dos ( 2.4 mg/kg daily 3 day ; 2.4 mg/kg initially , 12 hour Day 0 , daily Day 1 2 ) thereby establish safe , highly efficacious dose regimen use future clinical trial .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1 . Acute symptomatic Plasmodium falciparum malaria infection determine malaria smear parasite density ≥ 5000 asexual parasites/mL 2 . Age : 565 year old male female . 3 . Written informed consent must obtain adult age &gt; 18 year . Parental consent obtain child adolescent , subject assent also obtain adolescent ( age 1217 year ) . 4 . Willing stay hospitalize 4 day treatment 3 schedule followup outpatient visit Day 7 , 14 28 . 1 . Pregnant woman ( clinically positive urine βHCG ) nursing mother 2 . Clinical evidence severe malaria ( see Appendix B ) 3 . Mixed malaria infection admission malaria smear 4 . A previous history intolerance hypersensitivity study drug artesunate artemisinin derivatives Malarone . 5 . Efficacious malaria drug therapy administer past 30 day history ( i.e . quinine , mefloquine , lumefantrine artemisinin derivative ) 6 . Previous participation trial participation study involve investigational market product , concomitantly within 30 day prior entry study . 7 . Laboratory evidence history significant liver renal functional abnormality . 8 . Anyone receive transfusion blood product within 30 day 9 . Unable and/or unlikely comprehend and/or follow protocol . 10 . Likelihood require treatment study period drug permit study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>